51
|
Boldrini L, Bartoletti R, Giordano M, Manassero F, Selli C, Panichi M, Galli L, Farci F, Faviana P. C-MYC, HIF-1α, ERG, TKT, and GSTP1: an Axis in Prostate Cancer? Pathol Oncol Res 2018; 25:1423-1429. [PMID: 30357756 DOI: 10.1007/s12253-018-0479-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2018] [Accepted: 10/04/2018] [Indexed: 12/13/2022]
Abstract
To analyze putative biomarkers for prostate cancer (PCA) characterization, the second leading cause of cancer-associated mortality in men. Quantification of the expression level of c-myc and HIF-1α was performed in 72 prostate cancer specimens. A cohort of 497 prostate cancer patients from The Cancer Genome Atlas (TCGA) database was further analyzed, in order to test our hypothesis. We found that high c-myc level was significantly associated with HIF-1α elevated expression (p = 0.008) in our 72 samples. Statistical analysis of 497 TCGA prostate cancer specimens confirmed the strong association (p = 0.0005) of c-myc and HIF-1α expression levels, as we found in our series. Moreover, we found high c-myc levels significantly associated with low Glutatione S-transferase P1 (GSTP1) expression (p = 0.01), with high Transketolase (TKT) expression (p < 0.0001). High TKT levels were found in TCGA samples with low GSTP1 mRNA (p < 0.0001), as shown for c-myc, and with ERG increased expression (p = 0.02). Finally, samples with low GSTP1 expression displayed higher ERG mRNA levels than samples with high GSTP1 score (p < 0.0001), as above shown for c-myc. Our study emphasizes the notion of a potential value of HIF-1α and c-myc as putative biomarkers in prostate cancer; moreover TCGA data analysis showed a putative crosstalk between c-myc, HIF-1α, ERG, TKT, and GSTP1, suggesting a potential use of this axis in prostate cancer.
Collapse
Affiliation(s)
- L Boldrini
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Roma 57, 56126, Pisa, Italy.
| | - R Bartoletti
- Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy
| | - M Giordano
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Roma 57, 56126, Pisa, Italy
| | - F Manassero
- Division of Urology, Pisa University, Pisa, Italy
| | - C Selli
- Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy
| | - M Panichi
- Department of Radiotherapy, Pisa University, Pisa, Italy
| | - L Galli
- Division of Medical Oncology, Pisa University, Pisa, Italy
| | - F Farci
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Roma 57, 56126, Pisa, Italy
| | - P Faviana
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Roma 57, 56126, Pisa, Italy
| |
Collapse
|